Compugen Ltd. (NASDAQ:CGEN) Receives Average Rating of “Buy” from Brokerages

Compugen Ltd. (NASDAQ:CGEN) has earned a consensus rating of “Buy” from the five analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $5.00.

Several research firms have commented on CGEN. Weiss Ratings upgraded Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of Compugen in a report on Tuesday, August 4th.

Compugen Price Performance

Shares of CGEN stock opened at $2.35 on Wednesday. The company has a market capitalization of $222.19 million, a P/E ratio of 6.18 and a beta of 2.78. The company’s 50-day simple moving average is $2.46 and its two-hundred day simple moving average is $2.43. Compugen has a one year low of $1.40 and a one year high of $3.23.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.60 million during the quarter, compared to the consensus estimate of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. On average, research analysts expect that Compugen will post -0.28 EPS for the current fiscal year.

Institutional Trading of Compugen

A number of hedge funds have recently added to or reduced their stakes in CGEN. Platform Technology Partners lifted its stake in shares of Compugen by 10.0% during the 1st quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 5,000 shares during the last quarter. Glenmede Trust Co. NA boosted its position in Compugen by 187.5% during the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 22,500 shares in the last quarter. Bank Hapoalim BM purchased a new position in Compugen in the fourth quarter valued at about $37,000. Calamos Advisors LLC purchased a new position in Compugen in the first quarter valued at about $63,000. Finally, Hillsdale Investment Management Inc. bought a new position in Compugen in the first quarter worth about $68,000. 12.22% of the stock is owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. is an Israeli clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for cancer and other serious diseases. The company uses computational biology, data analysis and related technologies to identify novel drug targets and develop antibody-based medicines, with an emphasis on immuno-oncology.

Compugen’s pipeline includes investigational immune checkpoint therapies designed to reactivate anti-tumor immune responses. Its leading programs have included COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.